Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Prostaglandin E₂ Receptor EP₄ subtype is a widely expressed GPCR that mediates many physiological effects of PGE₂ through cAMP-dependent signaling but also engages additional pathways. Its diverse biological actions make it both an attractive therapeutic target for inflammatory diseases—and a molecule requiring caution due to potential tumor-promoting effects depending on disease setting.
Agonism or antagonism of EP4 receptor to modulate downstream signaling pathways including cAMP/PKA/CREB, PI3K/AKT/mTOR, ERK/MAPK, and p38 MAPK.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostaglandin E2 Receptor EP4 (EP4).